Organon & Co. (OGN)

Market Cap	2.39B
Revenue (ttm)	6.28B
Net Income (ttm)	700.00M
Shares Out	259.97M
EPS (ttm)	2.69
PE Ratio	3.42
Forward PE	2.41
Dividend	$0.08 (0.87%)
Ex-Dividend Date	Aug 15, 2025

Volume	233,714
Open	9.20
Previous Close	9.22
Day's Range	9.11 - 9.36
52-Week Range	8.01 - 23.10
Beta	0.56
Analysts	Hold
Price Target	18.00 (+96.08%)
Earnings Date	Aug 5, 2025

About SAGE

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 10,000
• Stock Exchange: NYSE
• Ticker Symbol: OGN
• Website: https://www.organon.com

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in IDR

Analyst Summary

According to 4 analysts, the average rating for OGN stock is "Hold." The 12-month stock price target is $18.0, which is an increase of 96.08% from the latest price.

Price Target

$18.0

(96.08% upside)

Analyst Consensus: Hold